Overview

Immunotherapy Drugs Market is poised to value USD 375551.47 million by 2028 end at a CAGR of 11% during the forecast period 2022 to 2028

The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market.

Major players included in the Immunotherapy Drugs Market:
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Merck & Co
• Novartis International AG
• Johnson & Johnson
• Sanofi
• GlaxoSmithKline Plc
• Amgen Inc.
• Abbvie Inc.
• Boehringer Ingelheim
• AstraZeneca
• Immatics Biotechnologies
• Biontech SE
• Genmab
• Gilead Sciences
• NBE Therapeutics
• Teva Pharmaceuticals
• Bayer
• Bristol-Myers Squibb
• Eli Lilly And Company
• Incyte Corporation                                                                                                                                                                                                                (Note: The list of the major players will be updated with the latest market scenario and trends)

Immunotherapy Drugs Market Segmentation:

By Type
• Checkpoint Inhibitors
• Adult Vaccines
• Interleukins
• Monoclonal Antibodies
• Interferons
• Alpha And Beta
• Others

By Therapy Area
• Cancer
• Infectious Diseases
• Autoimmune & Inflammatory Diseases

By End User
• Clinics
• Hospitals
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune & inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies.

Regional Analysis:

The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios.

Competitive Landscape:                            

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Immunotherapy Drugs Market By Type, By Therapy Area, By End-User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Immunotherapy Drugs Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Immunotherapy Drugs Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Immunotherapy Drugs Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Immunotherapy Drugs Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Checkpoint Inhibitors
   7.2. Adult Vaccines
   7.3. Interleukins
   7.4. Monoclonal Antibodies
   7.5. Interferons
   7.6. Alpha And Beta
   7.7. Others

8. Immunotherapy Drugs Market, By Therapy Area Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Cancer
   8.2. Infectious Diseases
   8.3. Autoimmune & Inflammatory Diseases

9. Immunotherapy Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital
   9.2. Clinics
   9.3. Others

10. North America Immunotherapy Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Immunotherapy Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Immunotherapy Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Immunotherapy Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. F. Hoffmann-La Roche Ltd.
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Pfizer Inc.
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Merck & Co
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. Novartis International AG
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. Johnson & Johnson
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          
    16.6. Sanofi
          16.6.1. Company Overview
          16.6.2. Product Portfolio
          16.6.3. SWOT Analysis
          16.6.4. Financial Overview
          16.6.5. Strategic Overview     
    16.7. GlaxoSmithKline Plc
          16.7.1. Company Overview
          16.7.2. Product Portfolio
          16.7.3. SWOT Analysis
          16.7.4. Financial Overview
          16.7.5. Strategic Overview
    16.8. Amgen Inc.
          16.8.1. Company Overview
          16.8.2. Product Portfolio
          16.8.3. SWOT Analysis
          16.8.4. Financial Overview
          16.8.5. Strategic Overview 
    16.9. Abbvie Inc.
          16.9.1. Company Overview
          16.9.2. Product Portfolio
          16.9.3. SWOT Analysis
          16.9.4. Financial Overview
          16.9.5. Strategic Overview
    16.10.Boehringer Ingelheim
          16.10.1. Company Overview
          16.10.2. Product Portfolio
          16.10.3. SWOT Analysis
          16.10.4. Financial Overview
          16.10.5. Strategic Overview
    16.11.AstraZeneca
          16.11.1. Company Overview
          16.11.2. Product Portfolio
          16.11.3. SWOT Analysis
          16.11.4. Financial Overview
          16.11.5. Strategic Overview          
    16.12.Immatics Biotechnologies
          16.12.1. Company Overview
          16.12.2. Product Portfolio
          16.12.3. SWOT Analysis
          16.12.4. Financial Overview
          16.12.5. Strategic Overview      
    16.13.Biontech SE
          16.13.1. Company Overview
          16.13.2. Product Portfolio
          16.13.3. SWOT Analysis
          16.13.4. Financial Overview
          16.13.5. Strategic Overview
    16.14.Genmab
          16.14.1. Company Overview
          16.14.2. Product Portfolio
          16.14.3. SWOT Analysis
          16.14.4. Financial Overview
          16.14.5. Strategic Overview
    16.15.Gilead Sciences
          16.15.1. Company Overview
          16.15.2. Product Portfolio
          16.15.3. SWOT Analysis
          16.15.4. Financial Overview
          16.15.5. Strategic Overview          
    16.16.NBE Therapeutics
          16.16.1. Company Overview
          16.16.2. Product Portfolio
          16.16.3. SWOT Analysis
          16.16.4. Financial Overview
          16.16.5. Strategic Overview  
    16.17.Teva Pharmaceuticals
          16.17.1. Company Overview
          16.17.2. Product Portfolio
          16.17.3. SWOT Analysis
          16.17.4. Financial Overview
          16.17.5. Strategic Overview 
    16.18.Bayer
          16.18.1. Company Overview
          16.18.2. Product Portfolio
          16.18.3. SWOT Analysis
          16.18.4. Financial Overview
          16.18.5. Strategic Overview      
    16.19.Bristol-Myers Squibb
          16.19.1. Company Overview
          16.19.2. Product Portfolio
          16.19.3. SWOT Analysis
          16.19.4. Financial Overview
          16.19.5. Strategic Overview 
    16.20.Eli Lilly And Company
          16.19.1. Company Overview
          16.19.2. Product Portfolio
          16.19.3. SWOT Analysis
          16.19.4. Financial Overview
          16.19.5. Strategic Overview 
    16.21.Incyte Corporation
          16.19.1. Company Overview
          16.19.2. Product Portfolio
          16.19.3. SWOT Analysis
          16.19.4. Financial Overview
          16.19.5. Strategic Overview 

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures